188476-33-7

Basic information

• Product Name: N-BOC-ALPHA-METHYL-D-SERINE METHYL ESTER
• Synonyms: N-BOC-ALPHA-METHYL-D-SERINE METHYL ESTER;N-BOC-A-METHYL -D-SERINE METHYL ESTER;N-Boc-2-Methyl-D-serine Methyl ester, 97%;(S)-2-(tert-ButoxycarbonylaMino)-3-hydroxy-2-Methylpropanoic acid Methyl ester
• CAS NO: 188476-33-7
• Molecular Formula: C₁₀H₁₉NO₅
• Molecular Weight: 233.26
• Mol File: 188476-33-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-BOC-ALPHA-METHYL-D-SERINE METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-ALPHA-METHYL-D-SERINE METHYL ESTER(188476-33-7)
• EPA Substance Registry System: N-BOC-ALPHA-METHYL-D-SERINE METHYL ESTER(188476-33-7)

Safety Data

• Hazardous Substances Data: 188476-33-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-BOC-ALPHA-METHYL-D-SERINE METHYL ESTER is used as a protecting group for the amino group in peptide synthesis for the development of new drug compounds. Its selective deprotection and functionalization capabilities are essential in the synthesis process, allowing for the creation of complex peptide structures with specific therapeutic properties.
Used in Organic Chemistry:
In the field of organic chemistry, N-BOC-ALPHA-METHYL-D-SERINE METHYL ESTER is used as a building block for the synthesis of various organic compounds. Its unique structure and reactivity make it a valuable component in the development of novel organic molecules with potential applications in various industries, including materials science, agrochemicals, and pharmaceuticals.
Used in Medicinal Chemistry:
N-BOC-ALPHA-METHYL-D-SERINE METHYL ESTER is employed as a key intermediate in the synthesis of bioactive molecules and drug candidates. Its ability to protect the amino group during peptide synthesis allows for the incorporation of D-serine derivatives into peptide sequences, which can lead to the discovery of new therapeutic agents with improved pharmacological properties, such as enhanced stability, selectivity, and bioavailability.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 177270-59-6 (S)-2-tert-Butoxycarbonylamino-3-methoxymethoxy-2-methyl-propionic acid methyl ester 
• 147316-32-3 (2S)-methyl 2-amino-3-hydroxy-2-methylpropanoate 
• 186581-53-3 diazomethane 
• 84311-19-3 (S)-2-tert-Butoxycarbonylamino-3-hydroxy-2-methyl-propionic acid 
• 3398-40-1 (S)-(+)-2-amino-2-methyl-3-hydroxypropanoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 74-88-4 methyl iodide 
• 902451-76-7 3-tert-butyl 4-methyl (S)-4-methyl-2-oxooxazolidine-3,4-dicarboxylate 
• 902451-75-6 methyl (S)-4-methyl-2-oxooxazolidine-4-carboxylate 
• 902451-73-4 methyl (R)-3-carbamoyloxy-2-methylpropanoate 
• 942150-87-0 C₁₃H₁₇NO₇S 
• 1263775-07-0 (S)-2-methylserine methyl ester (1S)-(+)-camphor-10-sulfonate 
• 108-24-7 acetic anhydride 

Downstream Products

• 205817-26-1 (S)-3-Benzyloxyamino-2-tert-butoxycarbonylamino-2-methyl-propionic acid methyl ester 

Relevant articles and documents

Facile stereospecific synthesis and biological evaluation of (S)- and (R)-2-amino-2-methyl-4-[123I]iodo-3-(E)-butenoic acid for brain tumor imaging with single photon emission computerized tomography

Both enantiomers of 2-amino-2-methyl-4-iodo-3-(E)-butenoic acid (IVAIB, 5) were radioiodoinated in 65-72% yield. (S)-IVAIB entered 9L gliosarcoma cells primarily via A-type transport in vitro with higher uptake than (R)-IVAIB. Biodistribution studies in rats with 9L gliosarcoma brain tumors demonstrated higher tumor to brain ratios with (S)-IVAIB (75:1 at 1 h) than (R)-IVAIB (7.7:1). In this model, (S)-IVAIB is superior to (R)-IVAIB and is a promising radiotracer for brain tumor imaging.

Method for producing an optically active homoserine deriv. α-

PROBLEM TO BE SOLVED: To provide a method for obtaining an optically-active α-alkylserine derivative from a 1,3-propanediol derivative. SOLUTION: The method is provided, which produces an optically-active α-alkylserine derivative, such as (R) or (S)

Complementary syntheses of N,O-protected-(S)-2-methylserine on a multikilogram scale

Two complementary and scalable approaches have been used to manufacture multikilogram quantities of N,O-protected-(S)-2-methylserine. The first approach uses a diastereomeric salt resolution of 2-methylserine methyl ester as the (1S)-(+)-camphorsulfonate salt, and was used to rapidly access 15 kg of (S)-3-tert-butoxycarbonyl-2,2,4-trimethyl-1,3-oxazolidine-4-carboxylic acid with >99% ee. The second approach involves a stereoselective enolate methylation of a chiral cyclic l-serine derivative under cryogenic conditions. The four-step telescoped process, starting from l-serine methyl ester, was used to manufacture 20 kg of (2R,4S)-2-tert-butyl-3-tert-butoxycarbonyl-4-methyl-1,3- oxazolidine-4-carboxylic acid in 52% overall yield and 98% ee. The advantages and disadvantages for scale-up of both approaches are discussed.

Enantioselective electrophilic amination of α-cyanothioacetates with azodicarboxylates catalyzed by an axially chiral guanidine base

An enantioselective electrophilic amination of α-substituted cyanothioacetates with azodicarboxylate is demonstrated using an axially chiral guanidine as a chiral Bronsted base catalyst. The corresponding product, having a quaternary stereogenie center at

AGONISTS OF THE SPHINGOSINE- 1- PHOSPHATE RECEPTOR (SLP)

The invention provides compounds of formula I and formula II, their preparation, a their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SlP receptors.

CHEMICAL COMPOUNDS

The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, a

Synthesis of an immunomodulator (+)-conagenin and its analogs

Stereoselective synthesis of an immunomodulator (+)-conagenin was achieved. Both amine and carboxylic acid moieties were prepared from commercially available optically active methyl 3-hydroxy-2-methylpropanoate using dirhodium(II)-catalyzed C-H amination

Asymmetric total syntheses of marine cyclic depsipeptide halipeptins A-D

Halipeptins A-D (1a-d) are a family of natural cyclic depsipeptides isolated from marine sponges. Total syntheses of these four compounds are detailed in this report. The key elements in this synthesis include the elaboration of the polysubstituted decanoic acid parts by two asymmetric aldol reactions, assembly of the N-methyl-δ-hydroxyisoleucine residue by using either aza-Claisen rearrangement or methylation of aspartates as the key steps, and macrocyclization at the polysubstituted decanoic acid alanine site.

Total synthesis of (+)-conagenin

The total synthesis of the immunomodulator, (+)-conagenin was achieved using, as a key step, a method developed by us for the synthesis of 2-methyl-1,3-diols via Ti(III)-mediated diastereo- and regioselective opening of trisubstituted 2,3-epoxy alcohols,

Synthesis and biological evaluation of two chemically modified peptide epitopes for the class i MHC protein HLA-B*2705

The T-cell receptor of a CD8+ T-cell recognises peptide epitopes bound by class I major histocompatibility complex (MHC) glycoproteins presented in a groove on their upper surface. Within the groove of the MHC molecule are 6 pockets, two of whi